A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Completed · Phase 1
Conditions studied: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
In brief
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
Key facts
- Study ID
- NCT02110355
- Run by
- Kartos Therapeutics, Inc.
- People needed
- 31
- Starts
- 2014-12-19
- Expected to finish
- 2018-12-27
- Last updated by the study team
- 2021-03-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Los Angeles, California, United States
- Research Site — Aurora, Colorado, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Chapel Hill, North Carolina, United States
- Research Site — Nashville, Tennessee, United States
- Research Site — North Sydney, New South Wales, Australia
- Research Site — Melbourne, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.